Celyad Oncology (XBRU:CYAD) Additional Paid-In Capital : €6.32 Mil(As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Additional Paid-In Capital?

Celyad Oncology's quarterly additional paid-in capital stayed the same from Jun. 2022 (€6.32 Mil) to Dec. 2022 (€6.32 Mil) and stayed the same from Dec. 2022 (€6.32 Mil) to Jun. 2023 (€6.32 Mil).

Celyad Oncology's annual additional paid-in capital declined from Dec. 2020 (€43.35 Mil) to Dec. 2021 (€6.32 Mil) but then stayed the same from Dec. 2021 (€6.32 Mil) to Dec. 2022 (€6.32 Mil).

Celyad Oncology Additional Paid-In Capital Historical Data

The historical data trend for Celyad Oncology's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Additional Paid-In Capital Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

206.15

43.35

6.32

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial															6.32	6.32	6.32	6.32	6.32

Celyad Oncology Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Celyad Oncology Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (XBRU:CYAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

1C0:Germany

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines